Medtronic (NYSE: MDT) today announced new data demonstrating the health economic benefits of its MiniMed 780G system. Findings highlighted the advanced hybrid closed-loop automated insulin delivery system’s benefits compared to the standard of care using multiple daily injections (MDI) with intermittently scanned continuous glucose monitoring (isCGM). MiniMed 780G, Medtronic’s latest-generation automated insulin delivery system, provides real-time […]
Diabetes
Glucose management company LifeScan emerges from Ch. 11
LifeScan announced today that it emerged from its Chapter 11 financial restructuring process as it looks to continue advancing its glucose management offerings. Malvern, Pennsylvania-based LifeScan said in July that it entered into a restructuring support agreement. To implement it, the company filed for Chapter 11. In October, the Chapter 11 bankruptcy reorganization plan received U.S. […]
Insulet appoints first chief corporate affairs officer
Insulet (Nasdaq:PODD) announced today that it appointed Cristal Downing as its new chief corporate affairs officer, effective today. In the newly created role at the automated insulin delivery system developer, Downing will build and lead a corporate affairs function aimed at strengthening Insulet’s corporate reputation, advancing business priorities, catalyzing customer value and deepening engagement with […]
Medtronic has a new head of investor relations, former head to join Diabetes spin-off MiniMed
![Medtronic named Ingrid Goldberg (right) as its new head of investor relations. Ryan Weispfenning (left) will leave to lead investor relations for MiniMed. [Images from LinkedIn]](https://www.drugdeliverybusiness.com/wp-content/uploads/2025/12/Medtronic-VP-Head-of-investor-relations-Ryan-Weispfenning-MiniMed-Ingrid-Goldberg-150x86.jpg)
Medtronic (NYSE: MDT) announced today that it named Ingrid Goldberg as its new VP and head of investor relations (IR). Goldberg’s appointment comes as Ryan Weispfenning, who previously held that role, elected to join the company’s Diabetes business and lead the IR function for the unit as it continues to work toward a separation from […]
Abbott expands Lingo OTC CGM to Android devices
Abbott (NYSE:ABT) announced today that it made its Lingo over-the-counter continuous glucose monitor (CGM) and app available for Android devices. The company already offered the Lingo biowearable for Apple iOS devices. Expanding to Android could bring Lingo to millions more people looking to access real-time glucose data. The Lingo app is now available for download […]
Beta Bionics makes iLet available with Dexcom G7 15 Day CGM
Beta Bionics (Nasdaq:BBNX) took to social media to announce the integration of its iLet Bionic Pancreas with Dexcom’s (Nasdaq:DXCM) G7 15 Day continuous glucose monitor (CGM). Dexcom received FDA clearance for people over the age of 18 years old in the U.S. in April for the 15-day version of its latest-generation sensor. Last month, the company announced its […]
Researchers say they can use imaging to measure blood glucose for people with diabetes
Researchers at MIT developed a non-invasive method for measuring blood glucose levels, potentially offering an alternative to fingersticks. Many people with diabetes today use continuous glucose monitors (CGMs) to keep track of their glucose levels. Those devices still have a small, minimally invasive interstitial needle inserted into the body when applied and don’t exceed a […]
Dexcom launches program to enhance healthcare provider CGM knowledge
Dexcom (Nasdaq:DXCM) today announced the launch of Dexcom Academy, a new, personalized learning platform for healthcare professionals (HCPs). Guided by HCP insights, the company designed Dexcom Academy to strengthen confidence in continuous glucose monitor (CGM) use. The San Diego-based CGM maker wants to support consistent, high-quality diabetes care without adding to clinical burden. The company […]
Insulet wins FDA clearance for Omnipod 5 algorithm enhancements
Insulet (Nasdaq:PODD) announced today that it received FDA 510(k) clearance for new enhancements to its Omnipod 5 system. The Acton, Massachusetts–based company said the updates to its tubeless, wearable automated insulin delivery patch pump’s algorithm include a new benchmark in tubeless diabetes technology with a lower, 100 mg/dL target glucose option. It also delivers a […]
Insulet makes Omnipod 5 available with Dexcom G7 15 Day CGM
Insulet (Nasdaq:PODD) today announced immediate compatibility between its Omnipod 5 system and the Dexcom (Nasdaq:DXCM) G7 15 Day CGM. Acton, Massachusetts-based Insulet, which has paired its pumps with previous versions of Dexcom continuous glucose monitors (CGMs), has offered Omnipod 5 with the initial version of G7 since early 2024. However, Dexcom received FDA clearance for people […]
